Drug intelligence / Profile preview

CY002

Development stage: Preclinical
Lead developer: Shanghai Chaoyang Pharmaceutical
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Topical

Overview

CY002 is a molecular glue degrader under development by Shanghai Chaoyang Pharmaceutical for the treatment of solid tumors. Currently in the discovery phase, the compound utilizes a targeted protein degradation (TPD) mechanism to induce the proteasomal degradation of specific pathogenic proteins by facilitating their interaction with E3 ubiquitin ligases. This modality aims to address oncogenic drivers that are difficult to inhibit using conventional small molecule approaches.

Targets

SLFN12 (Schlafen family member 12)PDE3A (Phosphodiesterase 3A)

Beyond the preview

Go deeper on CY002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CY002.

Explore the full profile